$2.02
Value $118M
FHTX and MRK stock compared: price, dividend, valuation and results, from SEC filings.
$2.02
Value $118M
$148.94
Value $368B
Foghorn Therapeutics (FHTX) has a market value of $118M and Merck & Company (MRK) $368B. Over the last year, with dividends, FHTX moved -56.7% and MRK +65.0%. The P/E is 20.7 for FHTX and 150.1 for MRK. Dividend yield: FHTX none, MRK 2.28%.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
FHTX$118M
MRK$368B
MRK is 3,113 times FHTX
Revenue, 12 months
FHTX$112M
MRK$67.4B
MRK is 601 times FHTX
Net income, 12 months
FHTX$9.4M
MRK$2.5B
MRK is 260 times FHTX
Operating margin
FHTX2.1%
MRK–
ROIC
FHTX–
MRK3.9%
P/E
FHTX20.7
MRK150.1
MRK is 7.3 times FHTX
Dividend yield
FHTX0.0%
MRK2.3%
2.3 points apart
5-year return
FHTX-85.1%
MRK+107.3%
192.4 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
FHTX-85.1%
MRK+107.3%
| Period | FHTXWith dividends | MRKWith dividends |
|---|---|---|
| 1 year since November 14, 2025 | -56.7%Price -56.7% | +65.0%Price +60.3% |
| 3 years since November 16, 2023 | -46.3%-18.7% a yearPrice -46.3% | +60.0%+17.0% a yearPrice +46.0% |
| 5 years since November 15, 2021 | -85.1%-31.7% a yearPrice -85.1% | +107.3%+15.7% a yearPrice +78.0% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
FHTXFoghorn TherapeuticsMRKMerck & Company
| Price | $2.02 | $148.94 |
|---|---|---|
| Market value | $118M | $368B |
| Enterprise value (EV) | $38M | $412B |
| P/E | 20.7 | 150.1 |
| P/E, 5-year median | – | 14.8 |
| P/B | – | 8.2 |
| EV/EBIT | 15.9 | 86.6 |
| Free cash flow yield | – | 4.0% |
| Revenue, 12 months | $112M | $67.4B |
|---|---|---|
| Net income, 12 months | $9.4M | $2.5B |
| Free cash flow, 12 months | -$84M | $14.7B |
| Earnings per share, 12 months | $0.10 | $0.98 |
| Revenue growth, year on year | 36.8% | 1.3% |
| Revenue growth a year, past | +135.1%over 5 years | +9.4%over 5 years |
| EPS growth a year, past | – | +21.2%over 5 years |
| Gross margin | – | 71.8% |
|---|---|---|
| Operating margin | 2.1% | – |
| Net margin | 8.4% | 3.6% |
| ROIC | – | 3.9% |
| ROE | – | 5.2% |
| Cash | $80M | $9.7B |
|---|---|---|
| Total debt | $44M | $53.8B |
| Net debt / EBITDA | -14.1 | 5.7 |
| Interest cover | – | 2.4× |
| Dividend yield | – | 2.3% |
|---|---|---|
| Dividend per share, 12 months | – | $3.40 |
| Dividend growth a year, past | – | +5.8%over 5 years |
| Buyback yield | – | 1.4% |
| Shareholder yield | – | 3.7% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, Merck & Company ($368B) is about 3,113.2 times Foghorn Therapeutics ($118M), at today's prices.
Since November 15, 2021, FHTX's price moved -85.1% and MRK's +78.0%. With dividends: FHTX -85.1% (-31.7% a year), MRK +107.3% (+15.7% a year). Past returns do not predict future ones.
The dividend yield at today's price is none for Foghorn Therapeutics and 2.28% for Merck & Company. Over the last twelve months they paid – and $3.40 per share.
At today's price, the P/E is 20.7 for FHTX and 150.1 for MRK. It is the share price over the last twelve months' earnings per share.
Over the last twelve months, the net margin was 8.4% for Foghorn Therapeutics and 3.6% for Merck & Company, and the operating margin 2.1% and –. Revenue was $112M and $67.4B.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.